E75.21 Fabry (-Anderson) disease

Name of the Condition

• Fabry (-Anderson) disease (ICD-10 Code: E75.21)

Summary

Fabry disease is a rare X-linked lysosomal storage disorder caused by the deficiency of the enzyme alpha-galactosidase A. This deficiency leads to the accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in various tissues, including the kidneys, heart, nervous system, and skin. The condition typically presents with progressive organ damage, with symptoms often emerging in childhood or adolescence, though severity varies widely among individuals.

Causes

Fabry disease results from mutations in the GLA gene, which encodes the alpha-galactosidase A enzyme. These mutations impair the enzyme's ability to break down Gb3, leading to its buildup in cells. Inheritance is X-linked, meaning the condition primarily affects males, though carrier females may experience symptoms due to random X-chromosome inactivation.

Risk Factors

• Male sex (due to X-linked inheritance).
• Family history of Fabry disease or related lysosomal storage disorders.
• Ethnic backgrounds with higher carrier frequencies (e.g., certain populations with increased prevalence of GLA mutations).

Symptoms

• Acroparesthesias (burning pain in hands and feet), often triggered by heat, exercise, or fever.
• Gastrointestinal issues, including abdominal pain, diarrhea, or nausea.
• Skin manifestations, such as angiokeratomas (small, dark-red spots).
• Corneal verticillata (whorl-like opacities in the cornea).
• Progressive kidney dysfunction, leading to proteinuria or renal failure.
• Cardiac complications, including left ventricular hypertrophy or arrhythmias.
• Neurological symptoms, such as stroke or hearing loss.

Diagnosis

Diagnosis is confirmed through enzyme activity testing, which measures alpha-galactosidase A levels in blood or tissue. Genetic testing for GLA mutations is also used to identify carriers or confirm the diagnosis. Additional evaluations, including kidney biopsy, cardiac imaging, or neurological assessments, may be performed to assess organ involvement.

Treatment Options

Treatment focuses on managing symptoms and slowing disease progression. Enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A is available to reduce Gb3 accumulation. Supportive care includes pain management, renal replacement therapy for kidney failure, and cardiac or neurological interventions as needed. Emerging therapies, such as chaperone therapy or gene therapy, are under investigation.

Prognosis and Follow-Up

Prognosis varies depending on the timing of diagnosis and treatment. Early intervention with ERT can delay organ damage, but untreated or late-diagnosed individuals may experience significant complications, including renal failure or cardiovascular disease. Regular monitoring of kidney function, cardiac health, and neurological status is essential for managing the condition.

Complications

• End-stage renal disease requiring dialysis or transplantation.
• Cardiovascular events, such as heart attack or stroke.
• Hearing loss or vestibular dysfunction.
• Gastrointestinal complications, including chronic pain or malabsorption.
• Neurological impairment, including cognitive decline or peripheral neuropathy.

Lifestyle & Prevention

• Manage pain with appropriate medications and avoid triggers (e.g., extreme temperatures).
• Maintain a balanced diet and stay hydrated to support kidney health.
• Engage in regular physical activity, tailored to individual capacity, to support cardiovascular function.
• Attend regular medical follow-ups to monitor organ function and adjust treatment as needed.

When to Seek Professional Help

Seek medical attention if experiencing persistent pain, unexplained skin lesions, vision changes, or signs of organ dysfunction (e.g., swelling, fatigue, or shortness of breath). Early evaluation is critical for timely diagnosis and intervention.

Tips for Medical Coders

• Use E75.21 for Fabry (-Anderson) disease, ensuring the code aligns with clinical documentation of enzyme deficiency or genetic confirmation.
• Document specific manifestations (e.g., renal, cardiac, or neurological involvement) to support additional coding if applicable.
• Verify the patient's sex and family history, as these may influence diagnostic considerations and coding accuracy.